Rapid Micro Biosystems has announced it has secured $25 million in series C funding.
Rapid Micro Biosystems, based in Lowell, Mass., develops imaging technology that detects microbial contamination in the manufacture of pharmaceutical, biotechnology and other products
The financing round involved new investors Hepalink USA and Richard K. Mellon and Sons, along with continued participation from Kleiner Perkins Caufield & Byers, Longitude Capital, Quaker Partners, TPG Biotech and TVM Capital.
Rapid Micro Biosystems indicated the funding will go toward expanding global commercial and manufacturing operations in support of its Growth Direct System across the applications of environmental monitoring, sterility and bioburden testing. The Growth Direct System consists of an automated imaging instrument that analyzes user-prepared proprietary consumables.